This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PSivida CEO To Discuss Sustained Delivery And Nanotechnology In Ophthalmology At Upcoming Massachusetts Biotechnology Council Meeting

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr. Paul Ashton, will discuss “Cross Fertilization: Sustained Delivery and Nanotechnology in Ophthalmology” at an upcoming Formulation and Drug Delivery Committee Meeting of the Massachusetts Biotechnology Council on Wednesday, October 17.

Dr. Ashton’s presentation will focus on delivery of peptides and proteins, primarily in ophthalmology. Currently the eye space is dominated by two anti-VEGF proteins, Roche/Genentech’s Lucentis® and Regeneron’s Eyelea.® Both of these drugs must be repeatedly injected directly into the eye, typically every one to two months. “The development of a sustained release protein delivery system would offer a significant advantage in ophthalmology,” said Dr. Paul Ashton, president and chief executive officer of pSivida. “pSivida is presently developing such a delivery system, called Tethadur™, which is based on the company’s BioSilicon technology platform. This delivery system could also have a significant clinical impact outside of ophthalmology for diseases requiring systemic administration, particularly in the BioSimilars era.”

Tethadur is designed to provide sustained delivery of biologic molecules, including proteins, antibodies and peptides. It is composed of nanostructured porous material, in which the sizes of the pores are manufactured to accommodate specific protein, peptide or antibody molecules. “Very simply put, Tethadur can be viewed as a high tech egg box where each protein molecule is contained in its own spot until it is released,” said Dr. Ashton. “We are able to control the release rate of a drug by controlling the pore size of the Tethadur delivery material.”

pSivida recently announced a technology evaluation agreement with a leading global biopharmaceutical company to evaluate Tethadur in the field of ophthalmology. “Although we are at the very early stages with Tethadur, the potential improvement in patient care and clinical outcomes could be highly significant,” Dr. Ashton stated. “We have already been successful in this field, working with partners we have developed three of the four sustained release devices for ophthalmic drugs approved in either the US or the EU.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs